Background Metabolism disturbances are common in patients with depression. The drug metformin has been reported to exhibit antidepressant activity. Th......
期刊： PHARMACOPSYCHIATRY, 2021; 54 (02)
Background Patients with antipsychotic-naive first-episode (ANFE) schizophrenia (SZ) can help clarify many confounding factors in determining sex diff......
期刊： PHARMACOPSYCHIATRY, 2021; 54 (1)
Introduction Major smoking effects have been reported for a series of psychotropic agents, mainly including substrates of CYP450 1A2, although smoking......
期刊： PHARMACOPSYCHIATRY, 2020; 53 (2)
Background Polypharmacy including somatic medications such as proton pump inhibitors is a common phenomenon in psychiatric care. The aim of this study......
期刊： PHARMACOPSYCHIATRY, 2020; 53 (1)
Background Results of previous studies on the safety and efficacy of adjunctive reboxetine for schizophrenia have been inconsistent. Aim The aim of th......
期刊： PHARMACOPSYCHIATRY, 2019; 52 (1)
Introduction Weight gain is a common antipsychotic (AP)-related adverse drug reaction (ADR) that can increase the risk of cardiovascular diseases and ......
期刊： PHARMACOPSYCHIATRY, 2019; 52 (1)
Objective The purpose of this study was to evaluate the efficacy and safety of antipsychotic drugs for tic disorders (TDs) in a network meta-analysis.......
期刊： PHARMACOPSYCHIATRY, 2019; 52 (5)
Background The association between CYP2D6 metabolizer status and clinical outcomes of venlafaxine was extensively investigated previously, but no wide......
期刊： PHARMACOPSYCHIATRY, 2018; 51 (3)
Introduction The purpose of this study is to systematically review the efficacy and safety of adjunctive erythropoietin (EPO) in treating cognitive de......
